{"id":"NCT04186819","sponsor":"Blue Earth Diagnostics","briefTitle":"Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.","officialTitle":"A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-03-02","primaryCompletion":"2021-06-21","completion":"2021-06-21","firstPosted":"2019-12-05","resultsPosted":"2025-02-26","lastUpdate":"2025-02-26"},"enrollment":356,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"rhPSMA-7.3 (18F) Injection","otherNames":["No other interventions"]},{"type":"DIAGNOSTIC_TEST","name":"Positron Emission Tomography scan","otherNames":["PET scan"]}],"arms":[{"label":"Patients","type":"EXPERIMENTAL"}],"summary":"A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand in men with newly diagnosed prostate cancer.","primaryOutcome":{"measure":"Specificity","timeFrame":"Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration","effectByArm":[{"arm":"Efficacy Analysis Population","deltaMin":92.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":34,"countries":["United States","Finland","Germany","Netherlands"]},"refs":{"pmids":["37414702"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":356},"commonTop":["Headache","Injection site pain","Nausea","Hypertension","Tracheal deviation"]}}